Newbury Park, CA, United States of America

Christopher Haqq

USPTO Granted Patents = 4 


 

Average Co-Inventor Count = 3.6

ph-index = 1

Forward Citations = 7(Granted Patents)


Company Filing History:


Years Active: 2013-2025

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Christopher Haqq: Innovator in Cancer Treatment

Introduction

Christopher Haqq is a notable inventor based in Newbury Park, CA (US). He has made significant contributions to the field of cancer treatment, particularly in ovarian cancer therapies. With a total of 4 patents to his name, Haqq's work focuses on innovative methods to improve patient outcomes.

Latest Patents

One of Haqq's latest patents involves the administration of an anti-activin-A compound to a subject. This invention relates to methods of treating ovarian cancer by evaluating the subject's expression levels of specific biomarkers or angiogenic factors. The patent outlines the administration of an anti-activin-A compound, such as an anti-activin-A antibody or an activin-A-binding receptor. In certain embodiments, at least two compounds are administered, where the first is an anti-activin A compound and the second is a chemotherapeutic agent, such as capecitabine. This innovative approach also includes methods for identifying subjects suitable for treatment.

Career Highlights

Throughout his career, Christopher Haqq has worked with prominent companies in the biotechnology sector, including Atara Biotherapeutics, Inc. and Amgen Inc. His experience in these organizations has contributed to his expertise in developing effective cancer therapies.

Collaborations

Haqq has collaborated with notable professionals in the field, including Huiquan Han and Isaac Ciechanover. These partnerships have further enhanced his research and development efforts in cancer treatment.

Conclusion

Christopher Haqq is a distinguished inventor whose work in cancer treatment has the potential to significantly impact patient care. His innovative approaches and collaborations reflect his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…